Hemostasis Today

June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Uday Sankar Akash Vankayala: Key Findings on IBD-Associated VTE Phenotypes and Inpatient Burden
Jun 11, 2026, 07:59

Uday Sankar Akash Vankayala: Key Findings on IBD-Associated VTE Phenotypes and Inpatient Burden

Uday Sankar Akash Vankayala, Resident Doctor at Staten Island University Hospital, shared a post on LinkedIn:

”I had the amazing opportunity to present our research at the Northwell Academic Competition and Research Symposium at the Donald and Barbara Zucker School of Medicine!

Our study, ‘Thrombotic Phenotypes and Inpatient Burden of Acute Venous Thromboembolism in Inflammatory Bowel Disease Patients,’ explored the inpatient trajectories and how IBD drive’s unique clot phenotypes.

Using the Nationwide Inpatient Sample (NIS) database we analyzed a massive cohort of over 435,000 acute VTE hospitalizations and uncovered some interesting findings:

Key Findings:

  • Hospitalized IBD patients had a 45% higher odds of Portal Vein Thrombosis and 27% higher odds of Renal Vein Thrombosis, driven by regional intestinal inflammation.
  • The IBD cohort was significantly younger (59.5 vs. 64.4 years) with fewer baseline comorbidities, yet they experience a tougher clinical course.
  • IBD patients had longer hospital stays (11.41 vs. 9.77 days) and higher rates of blood transfusions and central lines to manage complex IV therapies and chronic anemia.

The Big Picture:

While early prophylactic anticoagulation keeps in-hospital mortality low, these unique anatomical risks indicate an absolute need of patient-specific inpatient risk calculators and tailored thromboprophylaxis models for the IBD population.

A huge thank you to my incredible mentors, Dr. Hassan Al Moussawi and Dr. Suzanne El Sayegh, as well as my co-authors, for their guidance and support throughout this project!”

Uday Sankar Akash Vankayala: Key Findings on IBD-Associated VTE Phenotypes and Inpatient Burden

Stay updated with Hemostasis Today.